Overview: Mycoplasma genitalium TestIntroduction: The Mycoplasma genitalium Test detects Mycoplasma genitalium, a bacteria causing sexually transmitted infections, helping guide treatment for pelvic pain or discharge. Affecting 1 in 100 sexually active individuals, M. genitalium poses diagnostic challenges due to asymptomatic cases. Following 2023 Centers for Disease Control and Prevention (CDC) guidelines, it uses PCR for high accuracy, supporting bacteriology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in infectious disease.
Other Names: M. genitalium Detection Test, STI Assay.
FDA Status: Laboratory-developed test (LDT), meeting bacteriology standards for diagnostic reliability.
Historical Milestone: M. genitalium testing began in the 1990s with research by Jensen, who identified the bacterium. PCR advancements in the 2000s by Cepheid improved detection, surpassing earlier culture methods.
Purpose: Detects M. genitalium presence to diagnose STIs, guides antibiotic therapy, and evaluates patients with pelvic pain, aiming to resolve symptoms.
Test Parameters: M. genitalium presence
Pretest Condition: Fresh swab or urine sample required. Collect swab or urine. Report history of sexual activity.
Specimen: Urine (sterile container, 5-20 mL), Vaginal Swab (sterile swab/transport medium, 1-2 swabs); Swab or 10 mL urine in sterile container. Transport in a biohazard container.
Sample Stability at Room Temperature: 4 hours
Sample Stability at Refrigeration: 24 hours
Sample Stability at Frozen: Not recommended
Medical History: Document pelvic pain or discharge. Include current medications or sexual history.
Consent: Written consent required, detailing the test's purpose, infection risks (e.g., PID), and sample collection risks.
Procedural Considerations: Uses PCR to detect bacteria, requiring labs with thermal cyclers. Results available in 2-3 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample delay or contamination can affect results. Medications may alter detection, requiring correlation.
Clinical Significance: Positive result confirms M. genitalium infection, guiding therapy. Early treatment might prevent complications, while untreated cases lead to PID. Negative results may require other tests.
Specialist Consultation: Consult an infectious disease specialist or gynecologist for interpretation.
Additional Supporting Tests: Chlamydia test, culture, or PCR panel to confirm diagnosis.
Test Limitations: Specific to M. genitalium; correlation with symptoms needed. False negatives possible with low bacterial load.
References: CDC Guidelines, 2023; Journal of Clinical Microbiology, Jensen JS, 2022.
